PURPOSE: Phase I-II data regarding neoadjuvant cisplatin, 5-fluorouracil (5-FU), paclitaxel, and radiation (PFT-R) from our institution demonstrated encouraging pathologic complete response (pCR) rates. This article updates our experience with PFT-R, and compares these results to our experience with cisplatin, 5-FU, and radiation therapy (PF-R) in locally advanced esophageal cancer. PATIENTS AND METHODS: We searched the Massachusetts General Hospital cancer registry for esophageal cancer patients treated with radiation therapy and chemotherapy between 1994-2002. Records of patients treated with curative, neoadjuvant therapy were examined for chemotherapeutic regimen. Outcomes of patients treated with PF-R or PFT-R were assessed for response to therapy, toxicity, and survival. RESULTS: A total of 177 patients were treated with neoadjuvant therapy with curative intent; 164 (93%) received PF-R (n=81) or PFT-R (n=83). Median overall survival was 24 months. After a median follow-up of 54 months for surviving patients, 3-year overall survival was 40% with no significant difference between PF-R (39%) and PFT-R (42%). CONCLUSIONS: Our findings failed to demonstrate an improvement in pCR or survival with PFT-R vs. PF-R. These results do not support this regimen of concurrent neoadjuvant PFT-R in esophageal cancer, and suggest that further investigations into alternative regimens and novel agents are warranted.
PURPOSE: Phase I-II data regarding neoadjuvant cisplatin, 5-fluorouracil (5-FU), paclitaxel, and radiation (PFT-R) from our institution demonstrated encouraging pathologic complete response (pCR) rates. This article updates our experience with PFT-R, and compares these results to our experience with cisplatin, 5-FU, and radiation therapy (PF-R) in locally advanced esophageal cancer. PATIENTS AND METHODS: We searched the Massachusetts General Hospital cancer registry for esophageal cancerpatients treated with radiation therapy and chemotherapy between 1994-2002. Records of patients treated with curative, neoadjuvant therapy were examined for chemotherapeutic regimen. Outcomes of patients treated with PF-R or PFT-R were assessed for response to therapy, toxicity, and survival. RESULTS: A total of 177 patients were treated with neoadjuvant therapy with curative intent; 164 (93%) received PF-R (n=81) or PFT-R (n=83). Median overall survival was 24 months. After a median follow-up of 54 months for surviving patients, 3-year overall survival was 40% with no significant difference between PF-R (39%) and PFT-R (42%). CONCLUSIONS: Our findings failed to demonstrate an improvement in pCR or survival with PFT-R vs. PF-R. These results do not support this regimen of concurrent neoadjuvant PFT-R in esophageal cancer, and suggest that further investigations into alternative regimens and novel agents are warranted.
Authors: Kfir Ben-David; George A Sarosi; Juan C Cendan; Drew Howard; Georgios Rossidis; Steven N Hochwald Journal: Surg Endosc Date: 2011-07-27 Impact factor: 4.584
Authors: David E Gannett; Ron F Wolf; Gary W Takahashi; Jeannie Louie; Rick C Wagner; Fred S Ey; Michael M Owens; William E Johnson; David W Cook; Roger E Alberty Journal: Gastrointest Cancer Res Date: 2007-07
Authors: James M Cleary; Harvey J Mamon; Jackie Szymonifka; Raphael Bueno; Noah Choi; Dean M Donahue; Panos M Fidias; Henning A Gaissert; Michael T Jaklitsch; Matthew H Kulke; Thomas P Lynch; Steven J Mentzer; Jeffrey A Meyerhardt; Richard S Swanson; John Wain; Charles S Fuchs; Peter C Enzinger Journal: BMC Cancer Date: 2016-07-13 Impact factor: 4.430
Authors: Tao Wang; Jie Yu; Min Liu; Yanliang Chen; Caiyun Zhu; Lin Lu; Mingzhu Wang; Lingfeng Min; Xinxin Liu; Xizhi Zhang; Johannes A Gubat; Yong Chen Journal: Drug Des Devel Ther Date: 2019-02-05 Impact factor: 4.162